ATE126433T1 - Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen. - Google Patents

Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.

Info

Publication number
ATE126433T1
ATE126433T1 AT89109712T AT89109712T ATE126433T1 AT E126433 T1 ATE126433 T1 AT E126433T1 AT 89109712 T AT89109712 T AT 89109712T AT 89109712 T AT89109712 T AT 89109712T AT E126433 T1 ATE126433 T1 AT E126433T1
Authority
AT
Austria
Prior art keywords
alcoholism
treatment
acid salts
preparing pharmaceutical
compositions
Prior art date
Application number
AT89109712T
Other languages
English (en)
Inventor
Gian Luigi Gessa
Fabio Fadda
Di Campochiaro Chiara Mormile
Original Assignee
Ct Lab Farm Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Lab Farm Srl filed Critical Ct Lab Farm Srl
Application granted granted Critical
Publication of ATE126433T1 publication Critical patent/ATE126433T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89109712T 1988-06-03 1989-05-30 Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen. ATE126433T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20859/88A IT1217783B (it) 1988-06-03 1988-06-03 Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative

Publications (1)

Publication Number Publication Date
ATE126433T1 true ATE126433T1 (de) 1995-09-15

Family

ID=11173141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89109712T ATE126433T1 (de) 1988-06-03 1989-05-30 Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.

Country Status (16)

Country Link
US (1) US4983632A (de)
EP (1) EP0344704B1 (de)
AR (1) AR241512A1 (de)
AT (1) ATE126433T1 (de)
AU (1) AU633002B2 (de)
CA (1) CA1330423C (de)
DE (1) DE68923819T2 (de)
DK (1) DK174017B1 (de)
ES (1) ES2075011T3 (de)
FI (1) FI892718A7 (de)
GR (1) GR3018009T3 (de)
IT (1) IT1217783B (de)
NO (1) NO892270L (de)
NZ (1) NZ229399A (de)
PT (1) PT90732B (de)
ZA (1) ZA894128B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153219A (en) * 1991-04-22 1992-10-06 Morris D. Faiman Thiocarbamate sulfoxide composition for deterring ethanol ingestion
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
WO1993002682A1 (en) * 1991-08-06 1993-02-18 Labco Pharmaceuticals, Inc. Method and compositions for reducing craving for alcohol and stimulants
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
IT1261432B (it) * 1993-03-26 1996-05-23 Sigma Tau Ind Farmaceuti Uso di acil l- carnitina gammaidrossibutirrato per il trattamento dell'alcolismo.
IT1261485B (it) * 1993-06-24 1996-05-23 Sigma Tau Ind Farmaceuti Uso di acil l-carnitine gamma-idrossibutirrato per il trattamento di tossicodipendenze.
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
IT1283782B1 (it) * 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
EP1316309A1 (de) * 1998-12-23 2003-06-04 Orphan Medical Inc. Mikrobenbeständige und stabilisierte Lösungen die gamma-Hydroxybuttersäuresalze zur Behandlung von Narkolepsie enthalten
US6472431B2 (en) 1998-12-23 2002-10-29 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
PT1163019E (pt) 1999-03-25 2007-12-06 Metabolix Inc Dispositivos médicos e aplicações de polímeros de poli-hidroxialcanoato
US6623730B1 (en) 1999-09-14 2003-09-23 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
ITMI20020754A1 (it) * 2002-04-09 2003-10-09 Aboca S P A Composizioni effervescenti contenenti succhi di frutta essicati
RU2210360C1 (ru) * 2002-09-19 2003-08-20 Общество С Ограниченной Ответственностью "Консорциум-Пик" Психотропное средство
PT1638615E (pt) 2003-05-08 2015-02-04 Tepha Inc Fibras e tecidos médicos de polihidroxialcanoato
PT1778305E (pt) 2004-08-03 2010-07-27 Tepha Inc Suturas de poli-hidroxialcanoato que n†o se enrolam
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
US20100144885A1 (en) * 2006-09-29 2010-06-10 The Board Of Trustees Of The University Of Illinois Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
MX340591B (es) * 2010-05-04 2016-07-15 Jazz Pharmaceuticals Inc * Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CA2958747C (en) 2014-08-15 2022-08-16 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US9555155B2 (en) 2014-12-11 2017-01-31 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4658242A1 (de) 2023-02-03 2025-12-10 Tris Pharma, Inc. Natriumarmes oxybat zur einmaligen nacht

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044801B1 (de) * 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel

Also Published As

Publication number Publication date
EP0344704B1 (de) 1995-08-16
DK174017B1 (da) 2002-04-15
PT90732A (pt) 1989-12-29
AU633002B2 (en) 1993-01-21
DE68923819T2 (de) 1996-01-18
ZA894128B (en) 1990-03-28
DK272389A (da) 1989-12-04
NO892270D0 (no) 1989-06-02
CA1330423C (en) 1994-06-28
NO892270L (no) 1989-12-04
AU3590489A (en) 1989-12-07
DK272389D0 (da) 1989-06-02
FI892718A0 (fi) 1989-06-02
PT90732B (pt) 1994-10-31
AR241512A1 (es) 1992-08-31
US4983632A (en) 1991-01-08
FI892718L (fi) 1989-12-04
ES2075011T3 (es) 1995-10-01
NZ229399A (en) 1997-02-24
IT1217783B (it) 1990-03-30
DE68923819D1 (de) 1995-09-21
FI892718A7 (fi) 1989-12-04
IT8820859A0 (it) 1988-06-03
EP0344704A1 (de) 1989-12-06
GR3018009T3 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE59006880D1 (de) Gerät zur Herstellung von Formkörpern und Verwendung desselben zur Herstellung von Inlays, Onlays, und Kronen in der Zahnmedizin.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATA162587A (de) Verfahren zur herstellung von neuen benzolderivaten sowie von diese derivate enthaltenden pharmazeutischen zusammensetzungen und verfahren zur verringerung von entzündung bei tieren
DE3789973D1 (de) Zahnimplantat zur Befestigung von Zahnersatz-Suprakonstruktionen.
ATE96174T1 (de) Verfahren zur herstellung von avermectine-b und die verwendeten kulturen.
DE3777931D1 (de) Titandioxydsol und verfahren zur seiner herstellung.
DE68927949D1 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
DE3674582D1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylidid-hydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE127114T1 (de) Verfahren zur herstellung von pyrazolkarbonsäure und derivaten.
DE69125489D1 (de) Verwendung von derivaten durch menschliches gallensalz stimulierter lipase zur herstellung von medikamenten
ATE76636T1 (de) Verfahren zur herstellung von benzoesaeure und ihren salzen.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE3674585D1 (de) Zubereitung zur behandlung und vorbeugung von diarrhoee bei menschen und tieren und verfahren zu deren herstellung.
DE3773716D1 (de) Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE112276T1 (de) Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
AT388293B (de) Stabiles, zahnbelag verhinderndes zahnpflegemittel und verfahren zur herstellung desselben
DE68913779D1 (de) D-Amidase und Verfahren zur Herstellung von D-alpha-Alanin und/oder L-alpha-Alaninamid.
DE68920493D1 (de) Verfahren zur Herstellung von Derivaten von 2'-Deoxy-beta-cytidin und Salze davon.
DE3888697D1 (de) 2,3-thiomorpholinedion-2-oxim-derivate, arzneimittelzusammensetzungen und verfahren zur herstellung.
ATE57912T1 (de) Verfahren zur herstellung von anilinofumarat und 2,3-chinolindicarbonsaeure.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time